Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReTain: JNJ-64042056 in Preclinical Alzheimer's Disease
jRCT2031240382Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Arm A: JNJ-64042056 with Arm B: Placebo (2 arms). Primary endpoint: Change From Baseline in Brain Tau Burden by Tau PET. Started Mar 2025; status: active, not recruiting.
02
Drugs
ACI-35
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240382.